Home » Stocks » ACIU

AC Immune SA (ACIU)

Stock Price: $5.93 USD -0.19 (-3.10%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 425.43M
Revenue (ttm) 114.46M
Net Income (ttm) 46.85M
Shares Out 67.56M
EPS (ttm) -0.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $5.93
Previous Close $6.12
Change ($) -0.19
Change (%) -3.10%
Day's Open 6.13
Day's Range 5.87 - 6.18
Day's Volume 125,002
52-Week Range 4.24 - 9.65

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 month ago

Grant provides USD 600,000 in funding to support a world-class collaboration between AC Immune and Massachusetts General Hospital

GlobeNewsWire - 1 month ago

Prof. June is a world authority on immune tolerance and adoptive immunotherapy

GlobeNewsWire - 2 months ago

Prof. Streffer is a n established authority on n euroscience and b iomarker modalities

Zacks Investment Research - 2 months ago

AC Immune (ACIU) delivered earnings and revenue surprises of -16.67% and 32.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 2 months ago

Shares of AC Immune (NASDAQ:ACIU) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share were down 204.00% over the past year to ($0.26), which beat th...

GlobeNewsWire - 2 months ago

LAUSANNE, Switzerland, Nov. 13, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...

GlobeNewsWire - 2 months ago

Strategic partnership reflects AC Immune's growing expertise in monoclonal antibody development Strategic partnership reflects AC Immune's growing expertise in monoclonal antibody development

Zacks Investment Research - 2 months ago

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 2 months ago

AC Immune suffers setback on Alzheimer's front. Galera Therapeutics provides positive update of GC4419 in pancreatic cancer.

GlobeNewsWire - 3 months ago

Grant from the ‘ EU Joint Programme – Neurodegenerative Disease Research ’ (JPND) provides €1.45M in funding for the program

Zacks Investment Research - 3 months ago

The failure of AC Immune's (ACIU) study on Alzheimer's disease brings this challenging but promising space in focus.

24/7 Wall Street - 3 months ago

AC Immune S.A. (NASDAQ: ACIU) stock was absolutely crushed on Wednesday after one of the firm’s partners announced disappointing results from its midstage Alzheimer’s disease study.

Benzinga - 3 months ago

Shares of Swiss biopharma AC Immune SA (NASDAQ: ACIU) have lost about half their market capitalization on an adverse clinical readout for an out-licensed investigational Alzheimer's drug.

The Motley Fool - 3 months ago

AC Immune's experimental Alzheimer's-disease drug missed the mark in a midstage trial.

GlobeNewsWire - 3 months ago

Genentech disclosed that the anti-Tau antibody did not meet the co-primary efficacy endpoint or two secondary endpoints in the TAURIEL study ; the primary safety endpoint was met

GlobeNewsWire - 4 months ago

LAUSANNE, Switzerland, Sept. 11, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerat...

Zacks Investment Research - 4 months ago

Investors need to pay close attention to AC Immune (ACIU) stock based on the movements in the options market lately.

Zacks Investment Research - 5 months ago

AC Immune (ACIU) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research - 5 months ago

AC Immune (ACIU) delivered earnings and revenue surprises of 25.00% and 215.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 5 months ago

First-in-class TDP-43 antibody developed using SurpraAntigen™ platform

GlobeNewsWire - 5 months ago

AC Immune is one of three winners sharing USD 10 million through The Michael J. Fox Foundation Ken Griffin Alpha-synuclein Imaging Competition The award follows compelling preclinical resul...

GlobeNewsWire - 5 months ago

Next-generation PET tracer detects pathological alpha-synuclein with improved signal-to-noise ratio

GlobeNewsWire - 5 months ago

Presentations to highlight the Company’s broad expertise addressing both novel and well-established targets in neurodegenerative diseases Presentations to highlight the Company’s broad experti...

Zacks Investment Research - 6 months ago

AC Immune (ACIU) advances its Alzheimer's disease vaccine, ACI-35.030, to phase Ib/IIa study.

The Motley Fool - 6 months ago

Investors are excited about the company advancing its Alzheimer's disease vaccine, but caution is warranted.

Investors Business Daily - 6 months ago

AC Immune surged in massive volume Thursday after the small biotech company began dosing patients with an Alzheimer's treatment. The drug will be tested over 48 weeks in early-stage patients.

Benzinga - 6 months ago

Shares of Swiss biopharma AC Immune SA (NASDAQ: ACIU) were advancing strongly Thursday following a clinical trial update from the company.

GlobeNewsWire - 6 months ago

Interim data confirm the promising safety, tolerability and Tau-specific immunogenicity observed in the previous clinical study

GlobeNewsWire - 6 months ago

Results published in JAMA Neurology demonstrate the potential for a best-in-class diagnostic tool Results published in JAMA Neurology demonstrate the potential for a best-in-class diagnostic tool

GlobeNewsWire - 6 months ago

LAUSANNE, Switzerland, June 26, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerati...

Zacks Investment Research - 8 months ago

AC Immune (ACIU) delivered earnings and revenue surprises of 47.06% and 24.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 9 months ago

Latest appointment further reinforces the depth and breadth of the Company’s clinical development competences in Down syndrome-related Alzheimer’s disease Latest appointment further reinforces...

Zacks Investment Research - 11 months ago

AC Immune (ACIU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research - 11 months ago

Top Ranked Momentum Stocks to Buy for January 30th

Other stocks mentioned: AGYS, AXP
Zacks Investment Research - 1 year ago

Here we highlight five biotech companies, which are expected to deliver positive earnings surprises in this earnings season.

Other stocks mentioned: ASND, EYEN, NGM, SAGE
Zacks Investment Research - 1 year ago

AC Immune (ACIU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 year ago

LAUSANNE, Switzerland, Oct. 24, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenera...

Zacks Investment Research - 1 year ago

Here we discuss six small-cap companies with promising candidates in their pipeline for Alzheimer's disease.

Other stocks mentioned: ITCI, VTVT
GlobeNewsWire - 1 year ago

Lilly to pay CHF30 million development milestone

GlobeNewsWire - 1 year ago

Next generation Tau tracer offers potential for earlier and more accurate diagnosis in Alzheimer’s and neurodegenerative diseases

GlobeNewsWire - 1 year ago

Company to Give an Oral Presentation at Michael J. Fox Foundation’s 13th Annual Parkinson’s Disease Therapeutics Conference Company to Give an Oral Presentation at Michael J. Fox Foundation’s ...

Zacks Investment Research - 1 year ago

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

AC Immune (ACIU) initiates phase I study of ACI-3024, a Tau Morphomer inhibitor, for the treatment of neurodegenerative diseases like Alzheimer's disease.

Seeking Alpha - 1 year ago

Alzheimer's disease is the devastating threat of modern era.

Zacks Investment Research - 1 year ago

AC Immune (ACIU) delivered earnings and revenue surprises of -36.09% and -29.52%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

AC Immune (ACIU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

About ACIU

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company's lead product candidate is crenezumab, a humanized, monoclonal, and conformation-... [Read more...]

Industry
Biotechnology
IPO Date
Sep 23, 2016
CEO
Andrea Pfeifer
Employees
115
Stock Exchange
NASDAQ
Ticker Symbol
ACIU
Full Company Profile

Financial Performance

Financial numbers in millions CHF.
Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for AC Immune stock is "Buy." The 12-month stock price forecast is 11.09, which is an increase of 87.02% from the latest price.

Price Target
$11.09
(87.02% upside)
Analyst Consensus: Buy